NO20085240L - C-fenyl-1-tioglucitolforbindelse - Google Patents
C-fenyl-1-tioglucitolforbindelseInfo
- Publication number
- NO20085240L NO20085240L NO20085240A NO20085240A NO20085240L NO 20085240 L NO20085240 L NO 20085240L NO 20085240 A NO20085240 A NO 20085240A NO 20085240 A NO20085240 A NO 20085240A NO 20085240 L NO20085240 L NO 20085240L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl group
- compound
- conh2
- pharmaceutically acceptable
- hydrogen atom
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 108091006277 SLC5A1 Proteins 0.000 abstract 2
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 108091006269 SLC5A2 Proteins 0.000 abstract 1
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006179971 | 2006-06-29 | ||
| PCT/JP2007/063031 WO2008001864A1 (en) | 2006-06-29 | 2007-06-28 | C-phenyl 1-thioglucitol compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20085240L true NO20085240L (no) | 2009-03-30 |
Family
ID=38845628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20085240A NO20085240L (no) | 2006-06-29 | 2008-12-15 | C-fenyl-1-tioglucitolforbindelse |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8115017B2 (ja) |
| EP (1) | EP2036901B1 (ja) |
| JP (1) | JP5152519B2 (ja) |
| KR (1) | KR20090023570A (ja) |
| CN (1) | CN101479254B (ja) |
| AU (1) | AU2007266078B2 (ja) |
| BR (1) | BRPI0713058A2 (ja) |
| CA (1) | CA2655937A1 (ja) |
| IL (1) | IL196101A0 (ja) |
| MX (1) | MX2008016231A (ja) |
| NO (1) | NO20085240L (ja) |
| NZ (1) | NZ573843A (ja) |
| RU (1) | RU2434862C2 (ja) |
| WO (1) | WO2008001864A1 (ja) |
| ZA (1) | ZA200810683B (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| MX2011000637A (es) | 2008-07-15 | 2011-05-02 | Theracos Inc | Derivados deuretados de bencilbenceno y metodos de uso. |
| PT2334687E (pt) * | 2008-08-28 | 2012-04-13 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
| RU2532330C2 (ru) * | 2009-04-16 | 2014-11-10 | Тайсо Фармасьютикал Ко., Лтд. | Фармацевтические композиции |
| US8669380B2 (en) | 2009-11-02 | 2014-03-11 | Pfizer Inc. | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| AU2013348233C1 (en) * | 2012-11-20 | 2018-09-06 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
| US10022389B2 (en) | 2013-02-04 | 2018-07-17 | Taisho Pharmaceutical Co., Ltd. | Prophylactic or therapeutic drug for constipation |
| CN107311992B (zh) * | 2013-09-09 | 2020-08-18 | 上海研健新药研发有限公司 | C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用 |
| CN106632235A (zh) * | 2015-02-11 | 2017-05-10 | 佛山市赛维斯医药科技有限公司 | 一类含甲氧苯基噻吩酰胺类结构的双靶点抑制剂及其用途 |
| CN106632234A (zh) * | 2015-02-11 | 2017-05-10 | 佛山市赛维斯医药科技有限公司 | 一类烷氧噻吩酰胺类双靶点抑制剂及其用途 |
| CN106699725A (zh) * | 2015-02-11 | 2017-05-24 | 佛山市赛维斯医药科技有限公司 | 一类苯基噻吩酰胺类sglt2/sglt1双靶点抑制剂及其用途 |
| CN106831703A (zh) * | 2015-02-11 | 2017-06-13 | 佛山市赛维斯医药科技有限公司 | 一种腈基噻吩酰胺甲苯类双靶点抑制剂及其用途 |
| CN110066302B (zh) | 2018-01-23 | 2022-12-27 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
| CN111630058B (zh) | 2018-01-31 | 2022-02-15 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0850948B1 (en) | 1996-12-26 | 2002-04-24 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivatives and process for preparing the same |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| SK287183B6 (sk) | 2000-03-17 | 2010-02-08 | Kissei Pharmaceutical Co., Ltd. | Glukopyranozyloxybenzylbenzenový derivát, farmaceutická kompozícia s jeho obsahom, ich použitie a medziprodukt |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| EP1400529A4 (en) * | 2001-05-30 | 2007-12-19 | Kissei Pharmaceutical | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF |
| TWI254635B (en) * | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| AU2003254847B2 (en) | 2002-08-08 | 2009-06-04 | Kissei Pharmaceutical Co., Ltd. | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| RU2322449C2 (ru) * | 2002-08-09 | 2008-04-20 | Тайсо Фармасьютикал Ко., Лтд. | ПРОИЗВОДНЫЕ АРИЛ 5-ТИО-β-D-ГЛЮКОПИРАНОЗИДА И ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА ПРИ ДИАБЕТЕ, СОДЕРЖАЩИЕ ИХ |
| DE10239029A1 (de) * | 2002-08-21 | 2004-03-04 | Coty B.V. | Kosmetische und dermatologische Zubereitung mit Proteinen zur Hautaufhellung |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| JP4606876B2 (ja) | 2002-08-27 | 2011-01-05 | キッセイ薬品工業株式会社 | ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途 |
| KR20050089156A (ko) * | 2002-12-04 | 2005-09-07 | 깃세이 야쿠힌 고교 가부시키가이샤 | 고혈당증에 기인하는 질환의 예방 또는 치료제 |
| JPWO2004089967A1 (ja) | 2003-04-01 | 2006-07-06 | 大正製薬株式会社 | ヘテロアリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬 |
| US7439232B2 (en) * | 2003-04-01 | 2008-10-21 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
| WO2004106352A1 (ja) | 2003-05-29 | 2004-12-09 | Taisho Pharmaceutical Co., Ltd. | アルドヘキソピラノース中間体の製造法 |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| US20080090863A1 (en) | 2004-09-30 | 2008-04-17 | Taisho Pharmaceutical Co., Ltd. | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor |
| WO2006051662A1 (ja) | 2004-11-09 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | チアゾール誘導体 |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
-
2007
- 2007-06-28 AU AU2007266078A patent/AU2007266078B2/en not_active Ceased
- 2007-06-28 CA CA002655937A patent/CA2655937A1/en not_active Abandoned
- 2007-06-28 KR KR1020087027879A patent/KR20090023570A/ko not_active Ceased
- 2007-06-28 BR BRPI0713058-9A patent/BRPI0713058A2/pt not_active IP Right Cessation
- 2007-06-28 CN CN2007800242564A patent/CN101479254B/zh not_active Expired - Fee Related
- 2007-06-28 WO PCT/JP2007/063031 patent/WO2008001864A1/ja not_active Ceased
- 2007-06-28 NZ NZ573843A patent/NZ573843A/en not_active IP Right Cessation
- 2007-06-28 MX MX2008016231A patent/MX2008016231A/es active IP Right Grant
- 2007-06-28 JP JP2008522631A patent/JP5152519B2/ja not_active Expired - Fee Related
- 2007-06-28 RU RU2009102832/04A patent/RU2434862C2/ru not_active IP Right Cessation
- 2007-06-28 US US12/305,157 patent/US8115017B2/en not_active Expired - Fee Related
- 2007-06-28 EP EP07767824.1A patent/EP2036901B1/en active Active
-
2008
- 2008-12-15 NO NO20085240A patent/NO20085240L/no not_active Application Discontinuation
- 2008-12-18 ZA ZA2008/10683A patent/ZA200810683B/en unknown
- 2008-12-21 IL IL196101A patent/IL196101A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008016231A (es) | 2009-01-16 |
| EP2036901B1 (en) | 2013-05-01 |
| US20100004465A1 (en) | 2010-01-07 |
| WO2008001864A1 (en) | 2008-01-03 |
| EP2036901A1 (en) | 2009-03-18 |
| BRPI0713058A2 (pt) | 2012-04-10 |
| AU2007266078B2 (en) | 2011-12-15 |
| CN101479254A (zh) | 2009-07-08 |
| EP2036901A4 (en) | 2009-11-18 |
| ZA200810683B (en) | 2010-02-24 |
| NZ573843A (en) | 2011-02-25 |
| CN101479254B (zh) | 2012-05-30 |
| CA2655937A1 (en) | 2008-01-03 |
| JPWO2008001864A1 (ja) | 2009-11-26 |
| KR20090023570A (ko) | 2009-03-05 |
| JP5152519B2 (ja) | 2013-02-27 |
| HK1130472A1 (en) | 2009-12-31 |
| RU2434862C2 (ru) | 2011-11-27 |
| US8115017B2 (en) | 2012-02-14 |
| AU2007266078A1 (en) | 2008-01-03 |
| IL196101A0 (en) | 2009-09-01 |
| RU2009102832A (ru) | 2010-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20085240L (no) | C-fenyl-1-tioglucitolforbindelse | |
| NO20084830L (no) | C-fenylglycitolforbindelse for behandling av diabetes | |
| NO20074012L (no) | 1-tio-D-glucitolderivater | |
| SG155961A1 (en) | Pyrazoles as 11-beta-hsd-1 | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| IL187005A0 (en) | Diacylglycerol acyltransferase inhibitors | |
| EP1400529A4 (en) | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF | |
| NO20074872L (no) | Pyrazoler | |
| WO2007060140A3 (en) | Inhibitors of diacyglycerol acyltransferase (dgat) | |
| WO2009010416A3 (en) | Inhibitors of 11b-hydroxysteroid dehydrogenase | |
| TW200833675A (en) | Nicotinamide derivatives | |
| WO2007082808A3 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| NO20062583L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
| NO20055680L (no) | Heksahydropyridoisokinoliner som DPP-IV-inhibitorer | |
| NO20064412L (no) | Kondensert heterocykelderivat, medisinsk sammensetning inneholdende det samme og medisinsk anvendelse derav | |
| TW200800936A (en) | Novel coumarin derivatives with antitumor activity | |
| NO20076254L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
| WO2008140099A1 (ja) | テトラゾイルオキシム誘導体および植物病害防除剤 | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| NO20075409L (no) | Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater | |
| UA94606C2 (ru) | Производные тиоксантина, композиция, которая их содержит, и их применение в терапии | |
| NO20062591L (no) | Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet | |
| NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
| CA2634005A1 (en) | N-hydroxyamide derivatives possessing antibacterial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |